136 related articles for article (PubMed ID: 7796583)
1. SEQPWR and SEQOPR: computer programs for design of maximum information trials based on group sequential logrank tests.
Kim K
Comput Methods Programs Biomed; 1995 Feb; 46(2):143-53. PubMed ID: 7796583
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D
J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727
[TBL] [Abstract][Full Text] [Related]
3. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
4. [Irinotecan].
Yokoyama A
Nihon Rinsho; 2002 May; 60 Suppl 5():339-42. PubMed ID: 12101684
[No Abstract] [Full Text] [Related]
5. Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.
Lara PN; Gandara DR; Natale RB
Clin Lung Cancer; 2006 Mar; 7(5):353-6. PubMed ID: 16640809
[No Abstract] [Full Text] [Related]
6. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
Ignatiadis M; Mavroudis D; Veslemes M; Boukovinas J; Syrigos K; Agelidou M; Agelidou A; Gerogianni A; Pavlakou G; Tselepatiotis E; Nikolakopoulos J; Georgoulias V
Clin Lung Cancer; 2005 Nov; 7(3):183-9. PubMed ID: 16354313
[TBL] [Abstract][Full Text] [Related]
7. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group.
Schiller JH; Adak S; Cella D; DeVore RF; Johnson DH
J Clin Oncol; 2001 Apr; 19(8):2114-22. PubMed ID: 11304763
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.
Lu C; Komaki R; Lee JS; Shin DM; Palmer JL; Coldman BJ; Pisters KM; Kurie JM; Fossella FV; Glisson BS
Clin Cancer Res; 2003 Jun; 9(6):2085-91. PubMed ID: 12796372
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
[TBL] [Abstract][Full Text] [Related]
10. Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial.
Tiseo M; Boni L; Ambrosio F; Camerini A; Vitale MG; Baldini E; Cinieri S; Zanelli F; Defraia E; Passalacqua R; Crino L; Dazzi C; Tibaldi C; Turolla GM; D'Alessandro V; Zilembo N; Riccardi F; Ardizzoni A;
Clin Lung Cancer; 2015 Jan; 16(1):67-70. PubMed ID: 25450879
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan in small-cell lung cancer--Japanese trials.
Fukuoka M; Masuda N; Kudoh S; Negoro S
Oncology (Williston Park); 2000 Jul; 14(7 Suppl 5):57-62. PubMed ID: 10981292
[TBL] [Abstract][Full Text] [Related]
12. New state of the art in small-cell lung cancer.
Tamura T
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):8-10. PubMed ID: 11221023
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for small cell lung cancer.
Sandler AB
Semin Oncol; 2003 Feb; 30(1):9-25. PubMed ID: 12635086
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
[TBL] [Abstract][Full Text] [Related]
15. Design and analysis of group sequential logrank tests in maximum duration versus information trials.
Kim K; Boucher H; Tsiatis AA
Biometrics; 1995 Sep; 51(3):988-1000. PubMed ID: 7548714
[TBL] [Abstract][Full Text] [Related]
16. A simulated sequential analysis based on data from two MRC trials.
Donaldson AN; Whitehead J; Stephens R; Machin D
Br J Cancer; 1993 Dec; 68(6):1171-8. PubMed ID: 8260369
[TBL] [Abstract][Full Text] [Related]
17. Implementation of group sequential logrank tests in a maximum duration trial.
Lan KK; Lachin JM
Biometrics; 1990 Sep; 46(3):759-70. PubMed ID: 2242413
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan-cisplatin therapy for patients with extensive-stage small cell lung cancer: use patterns among American medical oncologists 2000-2006.
Green MR; Dowlati A; Yellamraju L; Daniels L; Willey J; Andrews M; Leff R
J Thorac Oncol; 2007 Oct; 2(10):953-6. PubMed ID: 17909359
[TBL] [Abstract][Full Text] [Related]
19. Lung cancer--time to move on from chemotherapy.
Carney DN
N Engl J Med; 2002 Jan; 346(2):126-8. PubMed ID: 11784881
[No Abstract] [Full Text] [Related]
20. [Role of irinotecan in the treatment of small cell carcinoma].
Crinò L
Tumori; 2001; 87(6):A35-7. PubMed ID: 11995707
[No Abstract] [Full Text] [Related]
[Next] [New Search]
